Cyteir Therapeutics Inc

NASDAQ CYT

Download Data

Cyteir Therapeutics Inc Current Assets to Total Assets Ratio 2 year CAGR for the year ending December 31, 2022: 5.00%

Cyteir Therapeutics Inc Current Assets to Total Assets Ratio 2 year CAGR is 5.00% for the year ending December 31, 2022, a 445.05% change year over year. The current assets to total assets ratio measures the proportion of a company's current assets in relation to its total assets. It is calculated by dividing current assets by total assets. This ratio indicates the percentage of a company's total assets that are in the form of current assets, such as cash, receivables, and inventory. It provides insights into the company's liquidity and the extent to which its assets are readily convertible to cash in the short term. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Cyteir Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2022 was 0.97, a -1.46% change year over year.
  • Cyteir Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2021 was 0.99, a 11.88% change year over year.
  • Cyteir Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2020 was 0.88, a -8.97% change year over year.
  • Cyteir Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2019 was 0.97.
NASDAQ: CYT

Cyteir Therapeutics Inc

CEO Mr. Joseph S. Zakrzewski
IPO Date June 18, 2021
Location United States
Headquarters 128 Spring Street, Lexington, MA, United States, 02421
Employees 46
Sector Healthcare
Industry Biotechnology
Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email